ZLAB

Zai Lab Limited

Price Chart

Latest Quote

$16.62

-0.72 (-4.15%)

Current Price

Previous Close	$17.34
Open	$16.66
Day High	$17.12
Day Low	$16.53
Volume	1,694,977

Fetched: 2026-06-06T00:03:20

Stock Information

Shares Outstanding	112.35M
Total Debt	$231.91M
Cash Equivalents	$661.32M
Revenue	$453.28M
Net Income	$-178.12M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.87B
EPS (TTM)	$-1.70
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$18.24B
Sales	$453.28M
Income	$-178.12M
Book/sh	$6.47
Cash/sh	$5.89
Employees	2K

Financial Ratios

Quick Ratio	1.84
Current Ratio	2.40
Debt/Eq	35.03

Returns & Margins

ROA	-13.36%
ROE	-24.19%
Gross Margin	8.11%
Operating Margin	-69.66%
Profit Margin	-39.29%

Ownership

Insider Ownership	1.99%
Institutional Ownership	29.18%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-9.52
P/S	4.12
P/B	2.57

Analyst Data

Recommendation	none
Target Price	$33.78

Technical Indicators

SMA20	$18.58
SMA50	$20.22
SMA200	$22.54
RSI	19.03
ATR	0.7748

Shares Float	978.72M
Short Float	4.71%
Short Ratio	6.10
Volatility	0.78
Rel Volume	1.87

Performance History

Week	-6.05%
Month	-20.89%
Quarter	-14.94%
6 Months	-15.85%
YTD	-4.10%
Year	-53.94%
3 Years	-48.85%
5 Years	-90.65%
10 Years	-40.49%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$16.62	1,694,977
2026-06-04	$17.34	666,200
2026-06-03	$17.17	584,300
2026-06-02	$17.15	1,768,800
2026-06-01	$17.09	914,900
2026-05-29	$17.69	913,800
2026-05-28	$18.48	959,400
2026-05-27	$18.69	716,600
2026-05-26	$18.45	557,100
2026-05-22	$18.61	390,000
2026-05-21	$19.10	427,600
2026-05-20	$18.81	834,300
2026-05-19	$18.37	626,600
2026-05-18	$18.86	1,649,200
2026-05-15	$20.59	903,100
2026-05-14	$20.33	1,054,800
2026-05-13	$20.47	759,000
2026-05-12	$19.53	465,000
2026-05-11	$19.59	984,200
2026-05-08	$18.60	1,255,200
2026-05-07	$19.76	1,269,100
2026-05-06	$21.01	1,054,700

About Zai Lab Limited

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

📰 Latest News

Zai Lab (ZLAB) Announces Senior Leadership Changes

Insider Monkey • 2026-06-05T21:03:25Z

Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week

MT Newswires • 2026-05-29T14:40:32Z

Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading

MT Newswires • 2026-05-18T14:44:01Z

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading

MT Newswires • 2026-05-15T14:38:39Z

Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading

MT Newswires • 2026-05-11T14:37:30Z

Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St. • 2026-05-11T13:58:42Z

Zai Lab Q1 Earnings Call Highlights

MarketBeat • 2026-05-09T09:05:19Z

Asian Equities Traded in the US as American Depositary Receipts Edge Higher Friday

MT Newswires • 2026-05-08T14:45:03Z

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks • 2026-05-07T13:30:07Z

Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-04-30T14:42:31Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$191,081,000	$147,860,000	$95,816,000	$74,018,000
Cost Of Revenue	$191,081,000	$147,860,000	$95,816,000	$74,018,000
Total Revenue	$460,156,000	$398,988,000	$266,719,000	$215,040,000
Operating Revenue	$499,206,000	$425,229,000	$298,911,000	$236,377,000
Expenses
Interest Expense	$5,209,000	$2,254,000	$0	$0
Total Expenses	$683,728,000	$672,935,000	$640,859,000	$607,926,000
Other Income Expense	$17,269,000	$-18,007,000	$-277,000	$-64,761,000
Other Non Operating Income Expenses	$-410,000	$3,235,000	$1,784,000	$594,000
Net Non Operating Interest Income Expense	$27,839,000	$34,851,000	$39,797,000	$14,582,000
Interest Expense Non Operating	$5,209,000	$2,254,000	$0	$0
Operating Expense	$492,647,000	$525,075,000	$545,043,000	$533,908,000
Other Operating Expenses	$-5,862,000	$-8,170,000	$-2,433,000	$-11,471,000
General And Administrative Expense	$277,605,000	$298,741,000	$281,608,000	$258,971,000
Selling And Marketing Expense	-	$123,783,000	$108,219,000	$61,512,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Net Interest Income	$27,839,000	$34,851,000	$39,797,000	$14,582,000
Interest Income	$33,048,000	$37,105,000	$39,797,000	$14,582,000
Normalized Income	$-194,806,708	$-241,966,000	$-329,770,000	$-386,883,000
Net Income From Continuing And Discontinued Operation	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Total Operating Income As Reported	$-229,434,000	$-282,117,000	$-366,573,000	$-404,357,000
Net Income Common Stockholders	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Net Income	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Net Income Including Noncontrolling Interests	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Net Income Continuous Operations	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Pretax Income	$-178,464,000	$-257,103,000	$-334,620,000	$-443,065,000
Special Income Charges	$0	$0	$10,000,000	$0
Earnings From Equity Interest	$-1,912,000	$-6,105,000	$2,789,000	$-8,952,000
Interest Income Non Operating	$33,048,000	$37,105,000	$39,797,000	$14,582,000
Operating Income	$-223,572,000	$-273,947,000	$-374,140,000	$-392,886,000
Gross Profit	$269,075,000	$251,128,000	$170,903,000	$141,022,000
Earnings From Equity Interest Net Of Tax	-	$0	$0	$-221,000
Per Share
Diluted EPS	$-1.60	$-2.60	$-3.50	$-4.60
Basic EPS	$-1.60	$-2.60	$-3.50	$-4.60
Other
Tax Effect Of Unusual Items	$321,292	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-177,836,000	$-227,856,000	$-320,741,000	$-378,435,000
Total Unusual Items	$19,591,000	$-15,137,000	$-4,850,000	$-56,403,000
Total Unusual Items Excluding Goodwill	$19,591,000	$-15,137,000	$-4,850,000	$-56,403,000
Reconciled Depreciation	$15,010,000	$11,856,000	$9,029,000	$8,227,000
EBITDA (Bullshit earnings)	$-158,245,000	$-242,993,000	$-325,591,000	$-434,838,000
EBIT	$-173,255,000	$-254,849,000	$-334,620,000	$-443,065,000
Diluted Average Shares	$109,531,109	$98,947,773	$96,639,413	$95,806,714
Basic Average Shares	$109,531,109	$98,947,773	$96,639,413	$95,806,714
Diluted NI Availto Com Stockholders	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Tax Provision	$-2,927,000	$0	$0	$0
Gain On Sale Of Ppe	$0	$0	$10,000,000	$0
Gain On Sale Of Security	$19,591,000	$-15,137,000	$-14,850,000	$-56,403,000
Research And Development	$220,904,000	$234,504,000	$265,868,000	$286,408,000
Selling General And Administration	$277,605,000	$298,741,000	$281,608,000	$258,971,000
Other Gand A	$112,600,000	$123,783,000	$108,219,000	$96,926,000
Salaries And Wages	$165,005,000	$174,958,000	$173,389,000	$162,045,000

Fetched: 2026-06-01

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$636,503,000	$781,964,000	$779,660,000	$1,037,192,000
Total Assets	$1,172,384,000	$1,185,753,000	$1,036,295,000	$1,220,140,000
Total Non Current Assets	$153,098,000	$135,273,000	$96,689,000	$95,804,000
Other Non Current Assets	$4,170,000	$6,882,000	$1,113,000	$803,000
Non Current Deferred Assets	$3,390,000	$0	-	-
Non Current Deferred Taxes Assets	$3,390,000	$0	-	-
Goodwill And Other Intangible Assets	$78,997,000	$58,934,000	$16,458,000	$8,403,000
Other Intangible Assets	$78,997,000	$58,934,000	$16,458,000	$8,403,000
Current Assets	$1,019,286,000	$1,050,480,000	$939,606,000	$1,124,336,000
Other Current Assets	$36,683,000	$41,527,000	$22,995,000	$35,674,000
Restricted Cash	$100,000,000	$100,000,000	$0	-
Inventory	$74,745,000	$39,875,000	$44,827,000	$31,621,000
Receivables	$118,285,000	$89,411,000	$65,333,000	$48,571,000
Notes Receivable	$12,169,000	$4,233,000	$6,134,000	$8,608,000
Accounts Receivable	$106,116,000	$85,178,000	$59,199,000	$39,963,000
Allowance For Doubtful Accounts Receivable	$-31,000	$-25,000	$-17,000	$-11,000
Gross Accounts Receivable	$106,147,000	$85,203,000	$59,216,000	$39,974,000
Cash Cash Equivalents And Short Term Investments	$689,573,000	$779,667,000	$806,451,000	$1,008,470,000
Cash And Cash Equivalents	$679,573,000	$449,667,000	$790,151,000	$1,008,470,000
Cash Equivalents	$1,215,000	$1,159,000	$1,100,000	$1,047,000
Cash Financial	$678,358,000	$448,508,000	$789,051,000	$1,007,423,000
Non Current Prepaid Assets	-	$1,284,000	$1,209,000	$1,396,000
Non Current Accounts Receivable	-	$1,351,000	-	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$224,259,000	$153,471,000	$15,151,000	$20,393,000
Long Term Debt And Capital Lease Obligation	$13,385,000	$13,712,000	$8,047,000	$13,343,000
Current Debt And Capital Lease Obligation	$210,874,000	$139,759,000	$7,104,000	$7,050,000
Current Debt	$204,530,000	$131,711,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$456,884,000	$344,855,000	$240,177,000	$174,545,000
Total Non Current Liabilities Net Minority Interest	$40,718,000	$45,470,000	$37,110,000	$34,703,000
Non Current Deferred Liabilities	$27,333,000	$31,433,000	$28,738,000	$21,360,000
Current Liabilities	$416,166,000	$299,385,000	$203,067,000	$139,842,000
Other Current Liabilities	$7,074,000	$6,352,000	$5,353,000	$4,054,000
Payables And Accrued Expenses	$198,218,000	$153,274,000	$190,610,000	$128,738,000
Payables	$147,397,000	$106,509,000	$132,453,000	$84,526,000
Other Payable	$486,000	$449,000	$2,474,000	$5,269,000
Total Tax Payable	$5,303,000	$5,154,000	$16,988,000	$13,283,000
Accounts Payable	$141,608,000	$100,906,000	$112,991,000	$65,974,000
Other Non Current Liabilities	-	$325,000	$325,000	-
Equity
Common Stock Equity	$715,500,000	$840,898,000	$796,118,000	$1,045,595,000
Total Equity Gross Minority Interest	$715,500,000	$840,898,000	$796,118,000	$1,045,595,000
Stockholders Equity	$715,500,000	$840,898,000	$796,118,000	$1,045,595,000
Gains Losses Not Affecting Retained Earnings	$29,697,000	$50,515,000	$37,626,000	$25,685,000
Other Equity Adjustments	$29,697,000	$50,515,000	$37,626,000	$25,685,000
Retained Earnings	$-2,628,620,000	$-2,453,083,000	$-2,195,980,000	$-1,861,360,000
Other
Treasury Shares Number	$7,433,210	$4,912,200	$4,912,200	$2,236,280
Ordinary Shares Number	$1,106,389,340	$1,077,702,540	$972,239,070	$960,219,570
Share Issued	$1,113,822,550	$1,082,614,740	$977,151,270	$962,455,850
Tangible Book Value	$636,503,000	$781,964,000	$779,660,000	$1,037,192,000
Invested Capital	$920,030,000	$972,609,000	$796,118,000	$1,045,595,000
Working Capital	$603,120,000	$751,095,000	$736,539,000	$984,494,000
Capital Lease Obligations	$19,729,000	$21,760,000	$15,151,000	$20,393,000
Total Capitalization	$715,500,000	$840,898,000	$796,118,000	$1,045,595,000
Treasury Stock	$29,053,000	$20,836,000	$20,836,000	$11,856,000
Additional Paid In Capital	$3,343,469,000	$3,264,295,000	$2,975,302,000	$2,893,120,000
Capital Stock	$7,000	$7,000	$6,000	$6,000
Common Stock	$7,000	$7,000	$6,000	$6,000
Non Current Deferred Revenue	$27,333,000	$31,433,000	$28,738,000	$21,360,000
Long Term Capital Lease Obligation	$13,385,000	$13,712,000	$8,047,000	$13,343,000
Current Capital Lease Obligation	$6,344,000	$8,048,000	$7,104,000	$7,050,000
Line Of Credit	$204,530,000	$131,711,000	$0	-
Current Accrued Expenses	$50,821,000	$46,765,000	$58,157,000	$44,212,000
Net PPE	$66,541,000	$69,457,000	$68,689,000	$78,771,000
Accumulated Depreciation	$-42,163,000	$-37,120,000	$-30,136,000	$-22,064,000
Gross PPE	$108,704,000	$106,577,000	$98,825,000	$100,835,000
Leases	$14,049,000	$11,306,000	$11,371,000	$11,300,000
Construction In Progress	$554,000	$25,129,000	$24,383,000	$25,647,000
Other Properties	$68,104,000	$68,716,000	$61,825,000	$62,709,000
Machinery Furniture Equipment	$1,401,000	$1,426,000	$1,246,000	$1,179,000
Buildings And Improvements	$24,596,000	$0	-	-
Properties	$0	$0	$0	$0
Finished Goods	$45,848,000	$24,063,000	$22,702,000	$12,156,000
Work In Process	$5,791,000	$2,544,000	$4,470,000	$436,000
Raw Materials	$23,106,000	$13,268,000	$17,655,000	$19,029,000
Other Short Term Investments	$10,000,000	$330,000,000	$16,300,000	$0
Investments And Advances	-	$3,115,000	$9,220,000	$6,431,000

Fetched: 2026-06-01

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-164,213,000	$-276,391,000	$-206,669,000	$-392,626,000
Operating Activities
Operating Cash Flow	$-150,789,000	$-214,869,000	$-198,178,000	$-367,642,000
Cash Flow From Continuing Operating Activities	$-150,789,000	$-214,869,000	$-198,178,000	$-367,642,000
Operating Gains Losses	$-19,049,000	$15,590,000	$4,601,000	$66,136,000
Investing Activities
Capital Expenditure	$-13,424,000	$-61,522,000	$-8,491,000	$-24,984,000
Investing Cash Flow	$307,866,000	$-375,193,000	$-10,776,000	$420,016,000
Cash Flow From Continuing Investing Activities	$307,866,000	$-375,193,000	$-10,776,000	$420,016,000
Financing Activities
Issuance Of Capital Stock	$0	$217,350,000	$0	$0
Financing Cash Flow	$72,353,000	$349,889,000	$-6,433,000	$-1,730,000
Cash Flow From Continuing Financing Activities	$72,353,000	$349,889,000	$-6,433,000	$-1,730,000
Net Other Financing Charges	$-9,266,000	$-1,983,000	$-8,802,000	$-7,600,000
Net Common Stock Issuance	$0	$217,350,000	$0	$0
Common Stock Issuance	$0	$217,350,000	$0	$0
Other
Repayment Of Debt	$-138,893,000	$-284,000	$0	$0
Issuance Of Debt	$206,837,000	$131,606,000	$0	$0
Interest Paid Supplemental Data	$4,878,000	$2,021,000	$0	$0
End Cash Position	$780,689,000	$550,781,000	$791,264,000	$1,009,273,000
Beginning Cash Position	$550,781,000	$791,264,000	$1,009,273,000	$964,903,000
Effect Of Exchange Rate Changes	$478,000	$-310,000	$-2,622,000	$-6,274,000
Changes In Cash	$229,430,000	$-240,173,000	$-215,387,000	$50,644,000
Proceeds From Stock Option Exercised	$13,675,000	$3,200,000	$2,369,000	$5,870,000
Net Issuance Payments Of Debt	$67,944,000	$131,322,000	$0	$0
Net Short Term Debt Issuance	$67,944,000	$131,322,000	$0	$0
Short Term Debt Payments	$-138,893,000	$-284,000	$0	$0
Short Term Debt Issuance	$206,837,000	$131,606,000	$0	$0
Net Investment Purchase And Sale	$321,203,000	$-313,700,000	$-16,300,000	$445,000,000
Sale Of Investment	$331,203,000	$16,300,000	$117,700,000	$705,274,000
Purchase Of Investment	$-10,000,000	$-330,000,000	$-134,000,000	$-260,274,000
Net Intangibles Purchase And Sale	$-5,323,000	$-55,865,000	$8,721,000	$-399,000
Sale Of Intangibles	$0	$0	$10,000,000	$0
Purchase Of Intangibles	$-5,323,000	$-55,865,000	$-1,279,000	$-399,000
Net PPE Purchase And Sale	$-8,014,000	$-5,628,000	$-3,197,000	$-24,585,000
Sale Of PPE	$87,000	$29,000	$4,015,000	$0
Purchase Of PPE	$-8,101,000	$-5,657,000	$-7,212,000	$-24,585,000
Change In Working Capital	$-54,707,000	$-68,390,000	$39,606,000	$-66,247,000
Change In Other Working Capital	$371,000	$5,146,000	$11,368,000	$-1,379,000
Change In Other Current Liabilities	$-3,051,000	$-31,281,000	$11,784,000	$-1,063,000
Change In Payables And Accrued Expense	$19,926,000	$-2,209,000	$36,803,000	$-53,773,000
Change In Payable	$19,926,000	$-2,209,000	$36,803,000	$-53,773,000
Change In Account Payable	$19,926,000	$-2,209,000	$36,803,000	$-53,773,000
Change In Prepaid Assets	$5,059,000	$-18,729,000	$12,246,000	$-19,785,000
Change In Inventory	$-47,028,000	$3,896,000	$-14,907,000	$-15,382,000
Change In Receivables	$-29,984,000	$-25,213,000	$-17,688,000	$25,135,000
Changes In Account Receivables	$-18,932,000	$-26,975,000	$-20,040,000	$4,330,000
Other Non Cash Items	$3,690,000	$5,599,000	$5,325,000	$5,748,000
Stock Based Compensation	$65,598,000	$70,651,000	$79,634,000	$61,302,000
Unrealized Gain Loss On Investment Securities	$1,912,000	$6,105,000	$-2,789,000	$8,952,000
Provisionand Write Offof Assets	$6,000	$8,000	$6,000	$1,000
Asset Impairment Charge	$12,288,000	$815,000	$1,030,000	$477,000
Depreciation Amortization Depletion	$15,010,000	$11,856,000	$9,029,000	$8,227,000
Depreciation And Amortization	$15,010,000	$11,856,000	$9,029,000	$8,227,000
Net Foreign Currency Exchange Gain Loss	$-19,591,000	$15,137,000	$14,850,000	$56,403,000
Gain Loss On Sale Of PPE	$542,000	$453,000	$-10,249,000	$560,000
Net Income From Continuing Operations	$-175,537,000	$-257,103,000	$-334,620,000	$-443,286,000
Earnings Losses From Equity Investments	-	$6,105,000	$-2,789,000	$9,173,000
Net Business Purchase And Sale	-	-	$0	$0
Purchase Of Business	-	-	$0	$0

Fetched: 2026-06-01